Clinical trial
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
NCT00673010 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 7, 2005
- Completion date
- October 2, 2025
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
thyroid cancer